A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients
Roberts R, Jurica K, Meyer W, Paxton H, Makuch R. A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients. The Journal Of Infectious Diseases 1990, 162: 638-642. PMID: 2117625, DOI: 10.1093/infdis/162.3.638.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase 1 studyDaily dosesAdverse reactionsTreatment groupsHuman immunodeficiency virus-infected patientsPatients' peripheral blood mononuclear cellsHIV surrogate markersT lymphocyte subsetsVirus-infected patientsClinical adverse reactionsAnti-HIV effectDemonstrable beneficial effectsHuman immunodeficiency virusBlood mononuclear cellsOral ribavirinP24 antigenemiaLymphocyte subsetsTotal lymphocytesSerum betaImmunodeficiency virusLymphocyte markersMononuclear cellsLymphocyte populationsSurrogate marker